What are the side effects of anagrelide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Side Effects of Anagrelide

Anagrelide causes frequent cardiovascular and gastrointestinal side effects that require careful monitoring, with headache (44%), palpitations (26%), and diarrhea (26%) being the most common adverse reactions. 1

Most Common Side Effects (≥5% incidence)

Based on FDA-approved labeling from clinical trials of 942 patients with myeloproliferative neoplasms, the following adverse reactions occur most frequently 1:

Cardiovascular Effects

  • Palpitations (26%) - most common cardiac side effect
  • Tachycardia (8%)
  • Chest pain (8%)

These cardiovascular effects result from anagrelide's direct vasodilating and positive inotropic properties as a phosphodiesterase-3 (PDE3) inhibitor 2, 3.

Neurological Effects

  • Headache (44%) - the single most common adverse reaction
  • Dizziness (15%)
  • Paresthesia (6%)

Gastrointestinal Effects

  • Diarrhea (26%)
  • Nausea (17%)
  • Abdominal pain (16%)
  • Vomiting (10%)
  • Flatulence (10%)
  • Anorexia (8%)
  • Dyspepsia (5%)

General/Constitutional Symptoms

  • Asthenia/weakness (23%)
  • Edema (21%) - includes peripheral edema (9%)
  • Pain (15%)
  • Fever (9%)
  • Malaise (6%)

Respiratory Effects

  • Dyspnea (12%)
  • Cough (6%)

Other Common Effects

  • Rash (8%)
  • Pruritus (6%)
  • Back pain (6%)

Serious Adverse Reactions

The most concerning serious adverse reactions involve cardiovascular complications 1:

  • Congestive heart failure
  • Myocardial infarction 4
  • Cardiomyopathy
  • Cardiomegaly
  • Complete heart block
  • Atrial fibrillation
  • Cerebrovascular accident
  • Pericardial effusion
  • Supraventricular tachycardia 5
  • Ventricular tachycardia
  • Torsades de pointes (post-marketing)

Pulmonary Complications

  • Pulmonary hypertension
  • Pleural effusion
  • Pulmonary infiltrates
  • Pulmonary fibrosis
  • Interstitial lung diseases (including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis) - post-marketing reports 1

Other Serious Events

  • Pancreatitis
  • Hepatotoxicity (symptomatic ALT/AST elevations >3× ULN) - post-marketing 1
  • Tubulointerstitial nephritis - post-marketing 1

Treatment Discontinuation

Approximately 17% (161/942) of patients discontinued anagrelide due to adverse reactions or abnormal laboratory results 1. The most common reasons for discontinuation were:

  • Headache
  • Diarrhea
  • Edema
  • Palpitations
  • Abdominal pain

Long-Term Safety Concerns

In a prospective 2-year study, side effects and toxic discontinuation rates were notably high 6:

  • 50% of patients continued treatment after 2 years
  • Side effects included palpitations (70%), headache (52%), nausea (35%), diarrhea/flatulence (33%), edema (22%), and fatigue (23%)

In young patients (<60 years) treated for over 10 years, anagrelide was associated with progressive anemia in CALR-mutated patients and new bone marrow fibrosis in JAK2-unmutated patients 7. This suggests limiting long-term use to JAK2-mutated patients with periodic monitoring for bone marrow fibrosis.

Less Common Adverse Reactions (1-5% incidence)

  • Flu symptoms, chills
  • Arrhythmia, angina pectoris, heart failure, syncope
  • Hemorrhage, hypertension, postural hypotension, vasodilatation
  • Constipation, gastrointestinal hemorrhage, gastritis
  • Anemia, thrombocytopenia, ecchymosis
  • Elevated liver enzymes
  • Arthralgia, myalgia
  • Depression, confusion, nervousness
  • Somnolence, insomnia, amnesia, migraine
  • Epistaxis, pneumonia
  • Alopecia
  • Abnormal vision, diplopia, tinnitus
  • Hematuria, renal failure

Pediatric Considerations

The frequency of adverse reactions in pediatric patients is similar to adults 1. The most common pediatric adverse reactions include:

  • Fever
  • Epistaxis
  • Headache
  • Fatigue
  • Episodes of increased pulse and decreased blood pressure (often asymptomatic)

Critical Monitoring Requirements

Given the side effect profile, patients on anagrelide require:

  • Cardiovascular monitoring - especially for patients with pre-existing cardiac disease
  • Avoid concomitant use with other PDE3 inhibitors (cilostazol, milrinone) or QT-prolonging drugs 8, 1
  • Bleeding risk assessment - particularly when combined with aspirin or antiplatelet agents 1
  • Hepatic and renal function monitoring - given post-marketing reports of hepatotoxicity and nephrotoxicity 1

The majority of gastrointestinal side effects (70-80%) occur within the first 2 weeks and are mild to moderate, with 60-65% resolving within the first month 1. This temporal pattern should guide patient counseling and early management strategies.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.